Initiator Pharma receives grant from Innovation Fund Denmark
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of psychogenic erectile dysfunction (ED), today announced that it has received a commitment from Innovation Fund Denmark to support the clinical development of IP2018. The Innobooster grant will fund the ongoing IP2018 phase 2a clinical trial with up to 3.8 MDKK.IP2018 is a candidate drug being developed for the treatment of sexual dysfunction in patients with major depressive disorder or more generally psychogenic ED. The Phase 2a trial is a randomized, double-blind, placebo-controlled, 3-way